Back to search results

Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Pancreatic Ductal Adenocarcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Baylor College of Medicine, Houston, Texas, United States

    Contact: Study coordinator (Ernest R. Camp, M.D., M.S.C.R., F.A.C.S.) · Ramsay.camp@bcm.edu · 713-798-7828
    Contact: Study coordinator (Benjamin Musher, M.D.) · blmusher@bcm.edu · 713-798-4292
    Contact: Principal Investigator (Ernest R Camp, M.D., M.S.C.R., F.A.C.S.)

  • Baylor St. Luke's Medical Center (BSLMC)., Houston, Texas, United States

    Contact: Study coordinator (Ernest R. Camp, M.D., M.S.C.R., F.A.C.S.) · Ramsay.camp@bcm.edu · 713-798-7828
    Contact: Study coordinator (Benjamin Musher, M.D.) · blmusher@bcm.edu · 713-798-4292
    Contact: Principal Investigator (Ernest R. Camp, M.D., M.S.C.R., F.A.C.S.)

  • Houston Methodist Hospital, Houston, Texas, United States

    Contact: Study coordinator (Safiya Joseph, CRC) · sdjoseph@houstonmethodist.org · 346-238-2420
    Contact: Principal Investigator (Nestor F Esnaola, M.D.)
Study leads

  • Ernest R. Camp, M.D., M.S.C.R., F.A.C.S.

    Principal Investigator

    Baylor College of Medicine

View source on ClinicalTrials.gov(opens in a new tab)